乳がん術前・術後化学療法としてのアントラサイクリン／シクロホスファミド併用療法に対する予防的制吐療法におけるアプレピタントおよびデキサメタゾンの有効性および安全性

DOI Web Site 被引用文献2件 参考文献18件 オープンアクセス

書誌事項

タイトル別名
  • Efficacy and Safety of Aprepitant and Dexamethasone in the Prevention of Nausea and Vomiting from Neoadjuvant or Adjuvant Anthracyclines and Cyclophosphamide Combination Therapy in Patients with Breast Cancer
公開日
2015
DOI
  • 10.5649/jjphcs.41.603
公開者
一般社団法人日本医療薬学会

この論文をさがす

説明

<p>Here we report the efficacy of the prophylactic antiemetic therapy that is recommended as high emetic risk by the American Society of Clinical Oncology (ASCO) guideline (2011) for anthracyclines and cyclophosphamide combination therapy (AC, CEF therapy) as neoadjuvant or adjuvant chemotherapy in breast cancer. In the National Cancer Center Hospital, aprepitant (APR) has been used in AC, CEF therapy since 2010, and additional day 2-4 dosages of dexamethasone (DEX) since 2012, following the ASCO guidelines (2006 / 2011). However, neither the efficacy nor the details of DEX dosage given concomitantly with APR in AC, CEF therapy have been fully established. We retrospectively investigated the incidence of nausea and vomiting before and after the introduction of APR therapy with or without additional use of DEX in breast cancer patients treated with preoperative or postoperative AC, CEF therapy in the hospital to confirm the efficacy and safety of the prophylactic antiemetic therapy. In 338 patients who received the treatment between January 2009 and December 2010, the incidence of vomiting decreased in the APR administered group (P = 0.020), while the degree of nausea increased (P = 0.003). In addition, in 369 patients who received the treatment between May 2011 and May 2013, the degree of nausea was significantly improved by APR with additional day 2-4 DEX dosages (P < 0.001). No adverse events associated with the additional dosage of DEX were observed. These results seem to positively support the efficacy of antiemetic prophylaxis recommended by the ASCO guideline (2011).</p>

収録刊行物

  • 医療薬学

    医療薬学 41 (9), 603-611, 2015

    一般社団法人日本医療薬学会

被引用文献 (2)*注記

もっと見る

参考文献 (18)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ